Skip to main content
. 2021 Nov 17;65(12):e00772-21. doi: 10.1128/AAC.00772-21

FIG 7.

FIG 7

Effects of hopeaphenol and remdesivir on SARS-CoV-2 variant replication in vitro using a CPE scoring-based assay. (A) Representative images of Vero-E6 cells following 4 days of infection with either SARS-CoV-2 variant B.1.1.7 (left) or B.1.351 (right) in the presence of 0.1% DMSO vehicle control (top), 0.7 nM REGN10933 or 3 μM remdesivir (middle), or 15 μM hopeaphenol (bottom). Scale bar = 100 μm. (B and C) Dose-response curves of REGN10933 in Vero-E6 cells following 4 days of infection with SARS-CoV-2 variant B.1.1.7 (B) or B.1.351 (C). (D and E) Dose-response curves of stilbenoids and remdesivir in Vero-E6 cells following 4 days of infection with SARS-CoV-2 variant B.1.1.7 (D) or B.1.351 (E). In panels B and C, data are presented relative to infected cells treated with 0.1% DMSO vehicle control. Results in panels B to E denote the mean ± SEM from at least 3 independent experiments.